BIO-key regains Nasdaq compliance; trading resumes July 8 after hearing panel decision

BIO KEY INTERNATIONAL INC

Nasdaq Hearings Panel determined BIO-key regained compliance with minimum bid price and SEC filing requirements.
Trading of BKYI common stock resumes on Nasdaq Capital Market on July 8, 2026.
Company subject to Discretionary Panel Monitor for one year until July 6, 2027.
CEO cites growing recurring revenue, solid financial position, and expects significantly improved results in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.